BioAll Medicine Completes Nearly Tens of Millions RMB Pre-A Financing to Advance Single-Cell Technologies in Clinical and Drug Development Applications

Recently, Tianjin Bio-Au Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Bio-Au Pharmaceutical”) announced that, following the completion of its angel round financing earlier this year, it has closed a Pre-A round financing of nearly RMB 10 million in December. This round was jointly invested by Bolian Capital and Shanghai Qingfeng Capital. The proceeds will support the company in advancing the translation of its single-cell diagnostic instrument and reagent platform, upgrading its technical analysis system, and further expanding its talent team and business scale.

BioMedicine is headquartered in the Binhai New Area of Tianjin, with a wholly-owned subsidiary and R&D and service centers in Beijing. The company was founded by a team of senior scientists specializing in single-cell high-throughput sequencing technology, dedicated toTo build China’s leading brand for single-cell oncology diagnosis and treatment, providing comprehensive solutions—including single-cell diagnostic instruments, diagnostic reagents, and medical diagnostic technology analysis—for both scientific research and clinical practice.Efficiently Empowering Personalized Diagnosis and Treatment of Cancer.

Since its establishment, the company has set up representative offices in multiple regional central cities across China, accelerating business development.It is one of the few teams in China to achieve substantial organic growth in both “R&D and market commercialization.”The company’s management, technical, and marketing teams possess extensive experience in providing services and conducting research and development in the field of single-cell analysis.He successfully led the establishment of China’s earliest and most experienced single-cell research service team,Has established in-depth collaborations with leading international single-cell platform companies, including 10X Genomics, BD, and Mission Bio, and possesses extensive expertise in technologies, products, and applications related to single-cell analysis.

Relying on a well-structured and experienced team of scientists, BioMed has achieved innovative development in single-cell sequencing technology, enabling moreRapidly and stably complete key single-cell technology workflows, ranging from sample processing, high-throughput single-cell isolation, and sequencing library construction to data analysis and clinical significance mining.Provides comprehensive technical solutions encompassing single-cell diagnostic instruments, diagnostic reagents, and medical diagnostic technology analysis.

Currently, the research and development and setup of BioMed’s independently developed projects—including the CELab automated single-cell labeling instrument, CELCode library preparation reagents, Tissue Prep tissue dissociation instrument, CELSCENE bioinformatics analysis software, and the single-cell database—are proceeding as planned. The successful completion of this round of financing will significantly accelerate BioMed’s market deployment and R&D progress in single-cell technology applications.